The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.
 
Hyunseok Kang
Honoraria - Cancer Expert Now; Cardinal Health
Consulting or Advisory Role - Bayer; Genentech; GlaxoSmithKline; Ignyta
Research Funding - Elevar Therapeutics (Inst); Exelixis (Inst); Kura Oncology (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Exelixis; Kura Oncology
 
Alan Loh Ho
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; CureVac; CureVac; Eisai; Genzyme; Merck; Novartis; Regeneron; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck
 
Jameel Muzaffar
No Relationships to Disclose
 
Daniel W. Bowles
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sung-Bae Kim
Honoraria - DAEHWA Pharmaceutical; Enzychem Lifesciences; ISU ABXIS
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; Enzychem Lifesciences (Inst); ISU Abxis; Lilly (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Kyowha Kirin (Inst); Novartis (Inst)
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Lilly; MSD; TAKEDA
Consulting or Advisory Role - Alpha pharmaceutical; AstraZeneca; Boehringer Ingelheim; Lilly; MSD; TAKEDA
 
Glenn J. Hanna
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Maverick Therapeutics; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exicure (Inst); Kartos Therapeutics (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Maverick Therapeutics; Regeneron
 
Francis P. Worden
Honoraria - Bayer; Bristol-Myers Squibb; CUE Biopharma; Eisai; LOXO; Merck Sharp & Dohme
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; CUE Biopharma; Eisai; Loxo; Merck; Rakuten Medical
Research Funding - Bristol-Myers Squibb; Eisai (Inst); Lilly; Loxo; Merck (Inst); Oragenics; Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Tak Yun
No Relationships to Disclose
 
Steven Norton
Employment - Elevar Therapeutics
Stock and Other Ownership Interests - Covance; Elevar Therapeutics
 
Neil Sankar
No Relationships to Disclose
 
Bhumsuk Keam
Consulting or Advisory Role - ABL Bio; AstraZeneca; Cellid; Genexine; MSD Oncology
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical